Price Alert

Halozyme Therapeutics Inc... (HALO)

NASDAQ: HALO · Real-Time Price · USD

66.78

1.24 (1.89%)

At close: Aug 15, 2025, 11:12 AM

Halozyme Therapeutics Statistics

Share Statistics

Halozyme Therapeutics has 116.97M shares outstanding. The number of shares has increased by -2.73% in one year.

Shares Outstanding	116.97M
Shares Change (YoY)	-2.73%
Shares Change (QoQ)	-0.25%
Owned by Institutions (%)	98.71%
Shares Floating	115.67M
Failed to Deliver (FTD) Shares	53
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 9.6M, so 7.79% of the outstanding shares have been sold short.

Short Interest	9.6M
Short % of Shares Out	7.79%
Short % of Float	10.67%
Short Ratio (days to cover)	6.16

Valuation Ratios

The PE ratio is 13.65 and the forward PE ratio is 8.22. Halozyme Therapeutics's PEG ratio is 0.21.

PE Ratio	13.65
Forward PE	8.22
PS Ratio	5.97
Forward PS	4.6
PB Ratio	16.67
P/FCF Ratio	12.95
PEG Ratio	0.21

Financial Ratio History

Enterprise Valuation

Halozyme Therapeutics has an Enterprise Value (EV) of 7.45B.

EV / Sales	7.34
EV / EBITDA	11.35
EV / EBIT	15.56
EV / FCF	15.91

Financial Position

The company has a current ratio of 7.8, with a Debt / Equity ratio of 4.14.

Current Ratio	7.8
Quick Ratio	6.78
Debt / Equity	4.14
Debt / EBITDA	2.29
Debt / FCF	3.21
Interest Coverage	30.48

Financial Efficiency

Return on Equity is 122.06% and Return on Invested Capital is 22.84%.

Return on Equity	122.06%
Return on Assets	21.52%
Return on Invested Capital	22.84%
Revenue Per Employee	$2.9M
Profits Per Employee	$1.27M
Employee Count	350
Asset Turnover	0.49
Inventory Turnover	1.12

Taxes

Income Tax	113.04M
Effective Tax Rate	20.29%

Stock Price Statistics

The stock price has increased by 12.22% in the last 52 weeks. The beta is 1.17, so Halozyme Therapeutics's price volatility has been higher than the market average.

Beta	1.17
52-Week Price Change	12.22%
50-Day Moving Average	56.05
200-Day Moving Average	55.76
Relative Strength Index (RSI)	70.58
Average Volume (20 Days)	2,478,474

Income Statement

In the last 12 months, Halozyme Therapeutics had revenue of 1.02B and earned 444.09M in profits. Earnings per share was 3.5.

Revenue	1.02B
Gross Profit	855.91M
Operating Income	551.48M
Net Income	444.09M
EBITDA	656.54M
EBIT	575.23M
Earnings Per Share (EPS)	3.5

Full Income Statement

Balance Sheet

The company has 115.85M in cash and 1.51B in debt, giving a net cash position of -1.39B.

Cash & Cash Equivalents	115.85M
Total Debt	1.51B
Net Cash	-1.39B
Retained Earnings	359.87M
Total Assets	2.05B
Working Capital	988.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 479.06M and capital expenditures -10.7M, giving a free cash flow of 468.37M.

Operating Cash Flow	479.06M
Capital Expenditures	-10.7M
Free Cash Flow	468.37M
FCF Per Share	3.69

Full Cash Flow Statement

Margins

Gross margin is 84.3%, with operating and profit margins of 54.32% and 43.74%.

Gross Margin	84.3%
Operating Margin	54.32%
Pretax Margin	54.87%
Profit Margin	43.74%
EBITDA Margin	64.66%
EBIT Margin	54.32%
FCF Margin	46.13%

Dividends & Yields

HALO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	7.32%
FCF Yield	7.72%

Dividend Details

Analyst Forecast

The average price target for HALO is $75, which is 19.2% higher than the current price. The consensus rating is "Buy".

Price Target	$75
Price Target Difference	19.2%
Analyst Consensus	Buy
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$87.5
Lynch Upside	39.07%
Graham Number	15.03
Graham Upside	-76.11%

Scores

Altman Z-Score	5.1
Piotroski F-Score	7